Menu
FDA · Medical device recall

Apellis Injection Kit 29g Injection Needle -single use intended to inject fluids into…

Oct. 11, 2023 Class II

Date
Oct. 11, 2023
Risk class
Class II (FDA's definition, 21 CFR 7.3(m): a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote)
Status
Ongoing
Filed by
Apellis Pharmaceuticals, Inc.
Product
Apellis Injection Kit 29g Injection Needle -single use intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin and either an 18-gauge or a 19-gauge 5 micron filter needle. Ref: IVT-KIT-29G
Reason
19-gauge x 1" inch filter needles showed appearances of a small fraction of non-preferred characteristics. A causal relationship has not been established between the structural variations in this 19-gauge filter needle and the rare events of retinal vasculitis
Distribution pattern
US Nationwide distribution.
Quantity
61,943 units
Codes and lots
UDI-DI: 00860008043672 Kit Lots: 223186 230036 230056 230236 230316 230326 230336 230406 231926 231946 231956 231986
Recall started
Aug. 22, 2023
Device type
Needle, Hypodermic, Single Lumen
Root cause (FDA)
Under Investigation by firm
What the company told customers
Apellis issued Medical Device Field Correction letters via email on 8/22/23 to Healthcare Practitioners and Distributors/Specialty Distributors and Pharmacy/ Logistics. The communication to the Healthcare Practitioners also includes update on the rare events of retinal vasculitis with real world use of SYFOVRE (pegcetacoplan injection). A causal relationship has not been established between the 19-gauge needle and the rare events of retinal vasculitis in the real world. Letter states reason for recall, health risk and action to take: Actions to be taken by the Customer/Distributor: Please note that as part of this field action, you are requested to: " Confirm your availability and participation by sending back an email to acknowledge receipt of this message. " Immediately cease distribution of the below injection kit lots and place any remaining inventory of the lots On Hold. " Provide a summary of current on-hand inventory of the injection kit lots below. " Provide a distribution report of the injection kit lots including customer name/address, lot shipped, quantity shipped, and date. Please provide the Distribution report in a maximum time of four business hours. Apellis will also be recommending that practitioners discontinue use of, and dispose, any remaining injection kits that contain the specific 19-gauge filter needle and recommend they instead use the injection kits containing the 18-gauge filter needle already in distribution. Apellis is now exclusively distributing injection kits with the 18-gauge filter needle. If you need to place a supplemental order to replace quarantined lots, please place them immediately through your normal ordering process and Apellis will expedite shipping replacement injection kits./ Apellis will also be notifying physicians that if they do not have an injection kit with the 18-gauge filter needle, they may request a new kit at no cost by emailing info@apellis.com or contacting their Apellis Territory Business Mana
Recall number
Z-2653-2023

What should I do? How serious is a recall? Classes and warnings explained

Source: FDA · Medical device enforcement report, recall number Z-2653-2023. The agency record governs; check it and the company before acting.

Report a mistake on this page